Firefly Neuroscience (NASDAQ:AIFF) Issues Earnings Results

Firefly Neuroscience (NASDAQ:AIFF) issued its quarterly earnings results on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, Zacks reports. Firefly Neuroscience had a negative return on equity of 319.00% and a negative net margin of 2,705.88%.The firm had revenue of $0.41 million for the quarter.

Firefly Neuroscience Stock Down 0.5%

Shares of Firefly Neuroscience stock traded down $0.01 during trading on Wednesday, reaching $2.17. The company’s stock had a trading volume of 1,773,696 shares, compared to its average volume of 10,155,839. Firefly Neuroscience has a 52-week low of $0.62 and a 52-week high of $4.51. The firm’s 50-day moving average is $1.28 and its two-hundred day moving average is $1.66. The company has a market cap of $30.86 million, a price-to-earnings ratio of -1.04 and a beta of 1.92.

Institutional Trading of Firefly Neuroscience

Several hedge funds have recently added to or reduced their stakes in AIFF. Geode Capital Management LLC grew its stake in shares of Firefly Neuroscience by 92.9% during the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after buying an additional 58,067 shares during the last quarter. Jane Street Group LLC purchased a new stake in Firefly Neuroscience during the 4th quarter valued at about $53,000. Finally, Vanguard Group Inc. boosted its holdings in Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after acquiring an additional 401,085 shares during the period. 4.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Firefly Neuroscience in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.